29.02

1.53% -0.45

Arcutis Biotherapeutics Inc (ARQT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché ARQT Giù? Forum Previsione

Precedente Chiudi:

$29.47

Aprire:

$29.35

Volume 24 ore:

1.73M

Relative Volume:

0.76

Capitalizzazione di mercato:

$3.55B

Reddito:

$59.61M

Utile/perdita netta:

$-262.14M

Rapporto P/E:

-7.4031

EPS:

-3.92

Flusso di cassa netto:

$-247.49M

1 W Prestazione:

-6.99%

1M Prestazione:

+23.75%

6M Prestazione:

+114.96%

1 anno Prestazione:

+136.90%

Intervallo 1D:

$28.30

$29.50

Intervallo di 1 settimana:

$28.30

$31.77

Portata 52W:

$11.13

$31.77

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Nome

Arcutis Biotherapeutics Inc

Settore

Healthcare (1123)

Industria

Biotechnology (627)

Telefono

805-418-5006

Indirizzo

3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA

Dipendente

342

Cinguettio

@ArcutisBio

Prossima data di guadagno

2024-12-06

Ultimi documenti SEC

ARQT's Discussions on Twitter

Confronta ARQT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ARQT Arcutis Biotherapeutics Inc	29.02	3.61B	59.61M	-262.14M	-247.49M	-3.92
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-07-25	Iniziato	Goldman	Neutral
2024-12-30	Iniziato	H.C. Wainwright	Buy
2024-08-28	Iniziato	Jefferies	Buy
2024-01-03	Aggiornamento	Mizuho	Neutral → Buy
2023-10-26	Downgrade	Mizuho	Buy → Neutral
2023-10-13	Downgrade	Goldman	Buy → Neutral
2022-09-07	Iniziato	Needham	Buy
2022-03-17	Iniziato	Goldman	Buy
2021-06-30	Iniziato	Mizuho	Buy
2021-05-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2020-11-09	Aggiornamento	Goldman	Neutral → Buy
2020-10-08	Iniziato	Truist	Buy
2020-02-25	Iniziato	Cantor Fitzgerald	Overweight
2020-02-25	Iniziato	Cowen	Outperform
2020-02-25	Iniziato	Goldman	Neutral
2020-02-25	Iniziato	Guggenheim	Buy

Mostra tutto

Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie

Dec 11, 2025

Tori Spelling Teams Up with Arcutis to Share Her Family’s Eczema Journey - WKEF

Dec 11, 2025

Looking Into Arcutis Biotherapeutics Inc's Recent Short Interest - Benzinga

Dec 11, 2025

Dec 10, 2025

What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now? - sharewise.com

Dec 10, 2025

Stempoint Capital LP Sells 334,401 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Dec 10, 2025

Dec 09, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected - simplywall.st

Dec 09, 2025

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri - BioSpace

Dec 09, 2025

Dec 08, 2025

Amit Munshi joins Arcutis board as founder Chaudhuri retires By Investing.com - Investing.com India

Dec 08, 2025

Arcutis strengthens board of directors with new appointment of Amit Munshi - marketscreener.com

Dec 08, 2025

Arcutis Strengthens Board of Directors with New Appointment - GlobeNewswire

Dec 08, 2025

Arcutis Biotherapeutics | 12/8/25 - Channel 13 Las Vegas News KTNV

Dec 08, 2025

Arcutis Biotherapeutics: The Earnings Inflection Has Arrived (ARQT) - Seeking Alpha

Dec 08, 2025

Dec 07, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 07, 2025

Dec 06, 2025

Arcutis Biotherapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis

Dec 06, 2025

XTX Topco Ltd Reduces Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Dec 06, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded to "Buy" Rating by Wall Street Zen - MarketBeat

Dec 06, 2025

Dec 05, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Reaches New 1-Year HighStill a Buy? - MarketBeat

Dec 05, 2025

What risks investors should watch in Arcutis Biotherapeutics Inc. stockRate Cut & Reliable Breakout Forecasts - Newser

Dec 05, 2025

Dec 04, 2025

Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat

Dec 04, 2025

Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 1,657 Shares - MarketBeat

Dec 04, 2025

Arcutis Biotherapeutics stock hits 52-week high at 31.29 USD - Investing.com

Dec 04, 2025

Arcutis Biotherapeutics stock hits 52-week high at 31.29 USD By Investing.com - Investing.com Canada

Dec 04, 2025

Dec 03, 2025

Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Bioth - GuruFocus

Dec 03, 2025

Assessing Arcutis Biotherapeutics (ARQT) Valuation After Its Strong 1-Year Share Price Surge - Yahoo Finance

Dec 03, 2025

Arcutis Biotherapeutics Insider Sold Shares Worth $302,133, According to a Recent SEC Filing - marketscreener.com

Dec 03, 2025

AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension - Finviz

Dec 03, 2025

Dec 02, 2025

Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock? - sharewise.com

Dec 02, 2025

Arcutis Biotherapeutics: Behind The Big Rally (NASDAQ:ARQT) - Seeking Alpha

Dec 02, 2025

(ARQT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com

Dec 02, 2025

American Century Companies Inc. Purchases 71,815 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat

Dec 02, 2025

Nov 29, 2025